Name | Role | Date | Shares | Price | Value |
---|---|---|---|---|---|
Shelia M. Violette | Chief Scientific Officer | 2024-10-15 | 6,000 | $7.29 | $43.74kBuy |
Shelia M. Violette | Chief Scientific Officer | 2024-10-11 | 4,574 | $3.12 | $14.27kBuy |
Shelia M. Violette | Chief Scientific Officer | 2024-10-08 | 13,300 | $3.12 | $41.50kBuy |
Name | Hold | Shares | Value | Type |
---|---|---|---|---|
Arch Venture Fund VIII LP | 47.29% | 5,768,694 | $8.94M | Insider |
James E. Flynn | 33.51% | 4,087,305 | $6.34M | Insider |
Diyong Xu | 18.47% | 2,252,987 | $3.49M | Insider |
Orbimed Advisors LLC | 18.47% | 2,252,987 | $3.49M | Insider |
Orbimed Advisors LLC | 18.47% | 2,252,987 | $3.49M | Institution |
Atlas Venture Life Science Advisors LLC | 17.15% | 2,092,106 | $3.24M | Institution |
Atlas Venture Fund X LP | 17.15% | 2,092,106 | $3.24M | Insider |
David S. Grayzel | 17.15% | 2,092,106 | $3.24M | Insider |
Carlyle Group Inc | 9.04% | 1,102,741 | $1.71M | Institution |
Mahendra Shah | 7.46% | 909,742 | $1.41M | Insider |